Keywords
literature review
stem cells
surgical treatment
bisphosphonates
orthopedics
children
How to Cite
Abstract
Objective. This study aims to analyze scientific literature on fibrous dysplasia (FD) and highlight the state of diagnosis and treatment of orthopedic pathology in patients with various forms of FD.
Materials and Methods. This article is based on a retrospective review of papers by various authors on the treatment of patients with FD. Articles were selected from scientific databases such as SCOPUS, Web of Science, and Google Scholar. The selected articles were reviewed in chronological order according to the topic of the study.
Results and Discussion. The article provides a systematic analysis of treatment approaches for patients with FD at different stages of the development of science. Modern diagnostic and therapeutic approaches are also analyzed, with particular attention given to the molecular-genetic aspects of the disease’s etiology, particularly mutations in the GNAS gene, which underlie bone growth regulation disorders. Current treatment approaches, including the use of bisphosphonates and various types of surgical interventions, are discussed.
Conclusions. A review of the scientific literature and analysis of historical aspects related to FD indicate both significant achievements of the orthopedic community in the diagnosis and treatment of FD, as well as significant challenges that will require further resolution. Changing views on the etiology and pathogenesis of the disease, as well as the identification of genetic mutations during early fetal development, have led to the recognition of FD as a stem cell disease. This provides new leverage for doctors and researchers to use stem cells in the treatment of patients with this pathology. Research on FD and the identification of this pathology as a result of stem cell disease has allowed scientists to explore new therapeutic approaches based on the use of mesenchymal stem cells (MSCs). MSCs can be used to correct bone tissue disorders since they can differentiate into osteoblasts and promote bone tissue remodeling. This opens the possibility for MSC transplantation or modification of their functioning to restore bone structures affected by FD. In our opinion, one promising area is the study of the osteogenic activity of MSCs from pathological sites, as this may help develop new regeneration strategies. There is a limited number of studies indicating the potential for bone defect reconstruction through the combination of MSCs and allomaterial.
References
Parekh SG, Donthineni-Rao R, Ricchetti E, Lackman RD. Fibrous Dysplasia. J Am Acad Orthop Surg. 2004;12(5):305-13. DOI: 10.5435/00124635-200409000-00005
Lichtenstein L. Polyostotic fibrous dysplasia. Arch Surg. 1938;36(5):874–98. doi: 10.1001/archsurg.1938.01190230153012.
Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction with precocious puberty in females. N Engl J Med. 1937;216:727.
Henry A. Monostotic fibrous dysplasia. J Bone Joint Surg Br. 1969;51-B(2):300-6. doi: 10.1302/0301-620X.51B2.300.
Hackett LJ, Christopherson WM. Polyostotic fibrous dysplasia. J Pediatr. 1949;35(6):767-71. doi: 10.1016/S0022-3476(49)80121-1.
Kransdorf MJ, Moser RP, Gilkey FW. Fibrous dysplasia. Radiographics. 1990;10(3):519–37. doi: 10.1148/radiographics.10.3.2188311.
Salpea P, Stratakis CA. Carney complex and McCune-Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol. 2014;386(1-2):85-91. doi: 10.1016/j.mce.2013.08.022.
Shi RR, Li XF, Zhang R, Chen Y, Li TJ. GNAS mutational analysis in differentiating fibrous dysplasia and ossifying fibroma of the jaw. Mod Pathol. 2013;26(8):1023-31.
Riminucci M, Robey PG, Saggio I, Bianco P. Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells. J Mol Endocrinol. 2010;45(6):355-64. doi: 10.1677/JME-10-0097.
Boyce AM, Collins MT. Fibrous dysplasia/McCune-Albright syndrome: a rare, mosaic disease of Gαs activation. Endocr Rev. 2020;41(2):345-70.
Fan QM, Yue B, Bian ZY, Xu WT, Tu B, Dai KR, et al. The CREB-Smad6-Runx2 axis contributes to the impaired osteogenesis potential of bone marrow stromal cells in fibrous dysplasia of bone. J Pathol. 2012;228(1):45-55. doi: 10.1002/path.4033.
Regard JB, Cherman N, Palmer D, Kuznetsov SA, Celi FS, Guettier JM, et al. Wnt/β-catenin signaling is differentially regulated by Gα proteins and contributes to fibrous dysplasia. Proc Natl Acad Sci U S A. 2011 13;108(50):20101-6. doi: 10.1073/pnas.1114656108.
Pereira TDSF, Diniz MG, França JA, Moreira RG, Menezes GHF, Sousa SF, et al. The Wnt/β-catenin pathway is deregulated in cemento-ossifying fibromas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(2):172-178. doi: 10.1016/j.oooo.2017.10.004.
Palmisano B, Spica E, Remoli C, Labella R, Di Filippo A, Donsante S, et al. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease. J Bone Miner Res. 2019;34(12):2171-2182. doi: 10.1002/jbmr.3828.
Meier ME, Hagelstein-Rotman M, Streefland TC, Winter EM, Bravenboer N, Appelman-Dijkstra NM. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome. Bone. 2023;171:116744. doi: 10.1016/j.bone.2023.116744.
Elias LSA, Costa RF, Carvalho MA, Batista AC, Silva TA, Leles CR, et al. Markers of bone remodeling in neoplastic and bone-related lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod [Internet]. 2010;110(6):44-51. doi:10.1016/j.tripleo.2010.06.014.
Robey PG, Kuznetsov S, Riminucci M, Bianco P. The role of stem cells in fibrous dysplasia of bone and the McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007;4 Suppl 4:386-94.
Riminucci M, Saggio I, Gehron Robey P, Bianco P. Fibrous dysplasia as a stem cell disease. J Bone Miner Res. 2006;21(Suppl 2):125-31. doi: 10.1359/jbmr.06s224.
Лазарев, І. А., Шидловський, М. С., Гук, Ю. М., Олійник, Ю. В., & Чеверда, А. І. (2015). Біомеханічний аналіз надійності фіксації проксимального відділу стегнової кістки при фіброзній дисплазії в умовах остеосинтезу різними типами фіксаторів (експериментальне дослідження). Травма, 2015;16(5):37-43, 37-43. doi: 10.22141/1608-1706.5.16.2015.79790.
Lazarev IA, Shydlovskyi MS, Huk YU, Oliinyk YV, Cheverda AI. Biomechanical analysis of the reliability of proximal femur fixation in fibrous dysplasia under osteosynthesis with various types of fixators (experimental study). Trauma. 2015;16(5):37-43. doi: 10.22141/1608-1706.5.16.2015.79790. [in Ukrainian]
Tripathy SK, Swaroop S, Velagada S, Priyadarshini D, Das RR, et al. Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia. Front Pediatr. 2020 24;8:582316. doi: 10.3389/fped.2020.582316.
Bertin H, Moussa MS, Komarova S. Efficacy of antiresorptive agents in fibrous dysplasia and McCune-Albright syndrome: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2023;24(6):1103-19. doi: 10.1007/s11154-023-09832-2.
Rotman M, Hamdy NA, Appelman-Dijkstra NM. Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone. Br J Clin Pharmacol. 2019;85(6):1169-79.
de Castro LF, Burke AB, Wang HD, Tsai J, Florenzano P, Pan KS, et al. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden. J Bone Miner Res. 2019;34(2):290-294. doi: 10.1002/jbmr.3602.
Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH. Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis. J Bone Miner Res. 2002;17(11):1949-53. doi: 10.1359/jbmr.2002.17.11.1949.
Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, et al. Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res. 2003;18(7):1235-46. doi: 10.1359/jbmr.2003.18.7.1235.
Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review. Drugs Aging. 1994;5(6):446-74. doi: 10.2165/00002512-199405060-00006.
Kos M, Luczak K, Godzinski J, Klempous J. Treatment of monostotic fibrous dysplasia with pamidronate. J Cranio-Maxillofac Surg. 2004;32(1):10-5.
Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343(8903):953-4. doi: 10.1016/S0140-6736(94)90069-8.
Classen CF, Mix M, Kyank U, Hauenstein C, Haffner D. Pamidronic acid and cabergoline as effective long-term therapy in a 12-year-old girl with extended facial polyostotic fibrous dysplasia, prolactinoma and acromegaly in McCune-Albright syndrome: a case report. J Med Case Rep. 2012;24;6:32. doi: 10.1186/1752-1947-6-32.
Kahn B, Cetner K, Su E, Figgie M. Hip resurfacing for treatment of advanced hip osteoarthritis in a patient with polyostotic fibrous dysplasia: five-year follow-up: a case report. Orthop Nurs. 2019;38(3):183-6. doi: 10.1097/NOR.0000000000000554.
Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006;21(Suppl 2):P114-P119. doi: 10.1359/jbmr.06s222.
Majoor BC, Appelman-Dijkstra NM, Fiocco M, van de Sande MA, Dijkstra PS, Hamdy NA. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. J Bone Miner Res. 2017;32(2):264-276. doi: 10.1002/jbmr.2999. doi: 10.1002/jbmr.2999.
Chapurlat RD, Legrand MA. Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone. 2021;143:115784. doi: 10.1016/j.bone.2020.115784.
Edgerton MT, Persing JA, Jane JA. The surgical treatment of fibrous dysplasia. Ann Surg. 1985;202(4):459-79.
Stephenson RB, London MD, Hankin FM, Kaufer H. Fibrous dysplasia: an analysis of options for treatment. J Bone Joint Surg Am. 1987;69:400-9.
Kusano T, Hirabayashi S, Eguchi T, Sugawara Y. Treatment strategies for fibrous dysplasia. J Craniofac Surg. 2009;20(3):768-70. DOI: 10.1097/scs.0b013e3181a14ca8
Stanton RP, Ippolito E, Springfield DS, Lindaman L, Wientoub S, Leet A. The surgical management of fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;7(Suppl 1):S1. doi: 10.1186/1750-1172-7-S1.
Zamri MF, Ng BW, Jamil K, Abd Rashid AH, Abd Rasid AF. Office Three-Dimensional Printed Osteotomy Guide for Corrective Osteotomy in Fibrous Dysplasia. Cureus. 2023;20;15(3):36384. doi: 10.7759/cureus.36384.
Patankar H, Patankar S, Tandon N, Bairy A. Fibrous dysplasia of radius bone-excision and fibula graft: a case report. J Orthop Case Rep. 2022;12(5):31-4. doi: 10.13107/jocr.2022.v12.i05.2804.
Leet AI, Boyce AM, Ibrahim KA, Wientroub S, Kushner H, Collins MT. Bone-Grafting in Polyostotic Fibrous Dysplasia. J Bone Joint Surg Am. 2016;3;98(3):211-9. doi: 10.2106/JBJS.O.00547.
Kim HY, Shim JH, Heo CY. A rare skeletal disorder, fibrous dysplasia: a review of its pathogenesis and therapeutic prospects. Int J Mol Sci. 2023;24(21):15591. doi: 10.3390/ijms242115591.
Jin YZ, Lee JH. Mesenchymal stem cell therapy for bone regeneration. Clin Orthop Surg. 2018;10(3):271-8. doi: 10.4055/cios.2018.10.3.271.
Dilogo IH, Kamal AF, Gunawan B, Rawung RV. Autologous mesenchymal stem cell transplantation for critical-sized bone defect following a wide excision of osteofibrous dysplasia. Int J Surg Case Rep. 2015;17:106-11. doi: 10.1016/j.ijscr.2015.10.039.
This work is licensed under a Creative Commons Attribution 4.0 International License.